Omnicell (NASDAQ:OMCL) Releases Q4 2024 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its fourth quarter 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.550-0.620 for the period, compared to the consensus EPS estimate of 0.470. The company issued revenue guidance of $295.0 million-$305.0 million, compared to the consensus revenue estimate of $287.9 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Omnicell Trading Up 0.1 %

Shares of NASDAQ:OMCL traded up $0.03 on Friday, reaching $48.67. 683,792 shares of the company traded hands, compared to its average volume of 528,146. The business’s 50-day simple moving average is $43.26 and its 200 day simple moving average is $35.17. The company has a quick ratio of 2.22, a current ratio of 1.05 and a debt-to-equity ratio of 0.47. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. Omnicell’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.29 earnings per share. Analysts expect that Omnicell will post 0.64 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on OMCL. Barclays lifted their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday. Benchmark reiterated a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum raised their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company upped their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Finally, StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $49.14.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.